

## CHEERS 2022 Checklist

Topic	No.	Item	Location where item is reported
<b>Title</b>			
	1	Identify the study as an economic evaluation and specify the interventions being compared.	p. 1
<b>Abstract</b>			
	2	Provide a structured summary that highlights context, key methods, results, and alternative analyses.	p. 2
<b>Introduction</b>			
<b>Background and objectives</b>	3	Give the context for the study, the study question, and its practical relevance for decision making in policy or practice.	p. 4–8
<b>Methods</b>			
<b>Health economic analysis plan</b>	4	Indicate whether a health economic analysis plan was developed and where available.	p. 8–12
<b>Study population</b>	5	Describe characteristics of the study population (such as age range, demographics, socioeconomic, or clinical characteristics).	p. 9–10
<b>Setting and location</b>	6	Provide relevant contextual information that may influence findings.	p. 8–9

Topic	No.	Item	Location where item is reported
<b>Comparators</b>	7	Describe the interventions or strategies being compared and why chosen.	p. 9–12
<b>Perspective</b>	8	State the perspective(s) adopted by the study and why chosen.	p. 9
<b>Time horizon</b>	9	State the time horizon for the study and why appropriate.	p. 9
<b>Discount rate</b>	10	Report the discount rate(s) and reason chosen.	p. 10
<b>Selection of outcomes</b>	11	Describe what outcomes were used as the measure(s) of benefit(s) and harm(s).	p. 9
<b>Measurement of outcomes</b>	12	Describe how outcomes used to capture benefit(s) and harm(s) were measured.	p. 9
<b>Valuation of outcomes</b>	13	Describe the population and methods used to measure and value outcomes.	p. 9–10
<b>Measurement and valuation of resources and costs</b>	14	Describe how costs were valued.	p. 10–12 – Supplementary Appendix
<b>Currency, price date, and conversion</b>	15	Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion.	p. 10
<b>Rationale and description of model</b>	16	If modelling is used, describe in detail and why used. Report if the model is publicly available and where it can be accessed.	p. 9
<b>Analytics and assumptions</b>	17	Describe any methods for analysing or statistically transforming data, any extrapolation methods, and approaches for validating any model used.	p. 10–12

Topic	No.	Item	Location where item is reported
<b>Characterising heterogeneity</b>	18	Describe any methods used for estimating how the results of the study vary for subgroups.	N/A
<b>Characterising distributional effects</b>	19	Describe how impacts are distributed across different individuals or adjustments made to reflect priority populations.	N/A
<b>Characterising uncertainty</b>	20	Describe methods to characterise any sources of uncertainty in the analysis.	p.12–13
<b>Approach to engagement with patients and others affected by the study</b>	21	Describe any approaches to engage patients or service recipients, the general public, communities, or stakeholders (such as clinicians or payers) in the design of the study.	N/A
<b>Results</b>			
<b>Study parameters</b>	22	Report all analytic inputs (such as values, ranges, references) including uncertainty or distributional assumptions.	p.12–13 – Table 1 and 4
<b>Summary of main results</b>	23	Report the mean values for the main categories of costs and outcomes of interest and summarise them in the most appropriate overall measure.	p.14 –Table 4
<b>Effect of uncertainty</b>	24	Describe how uncertainty about analytic judgments, inputs, or projections affect findings. Report the effect of choice of discount rate and time horizon, if applicable.	14–15
<b>Effect of engagement with patients and others affected by the study</b>	25	Report on any difference patient/service recipient, general public, community, or stakeholder involvement made to the approach or findings of the study	N/A

Topic	No.	Item	Location where item is reported
<b>Discussion</b>			
<b>Study findings, limitations, generalisability, and current knowledge</b>	26	Report key findings, limitations, ethical or equity considerations not captured, and how these could affect patients, policy, or practice.	15–18
<b>Other relevant information</b>			
<b>Source of funding</b>	27	Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis	19
<b>Conflicts of interest</b>	28	Report authors conflicts of interest according to journal or International Committee of Medical Journal Editors requirements.	19

*From:* Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. *Value Health* 2022;25. doi:10.1016/j.jval.2021.10.008

Article information: <https://dx.doi.org/10.21037/apm-23-240>

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.